Vertex Pharmaceuticals EVP Ourania Tatsis sells $142,547 in stock
BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...
Vertex Pharmaceuticals EVP sells shares worth $1.58 million
Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently executed a significant stock sale. According to a recent SEC filing, Biller ...
SpotDraft Secures $54 Million To Lead AI Contract Lifecycle Management
SpotDraft's Series B funding round, spearheaded by Vertex Ventures and Trident Partners, will accelerate the company's global ...
Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a ...
Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord yesterday
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...